APA

You R., Liu J., Wu D. B., Qian X., Lyu B., Zhang Y. & Luo N. (2019). Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China. : Cancer management and research.

Chicago

You Ruxu, Liu Jinyu, Wu David Bin-Chia, Qian XinYu, Lyu Boxiang, Zhang Yu and Luo Nan. 2019. Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China. : Cancer management and research.

Harvard

You R., Liu J., Wu D. B., Qian X., Lyu B., Zhang Y. and Luo N. (2019). Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China. : Cancer management and research.

MLA

You Ruxu, Liu Jinyu, Wu David Bin-Chia, Qian XinYu, Lyu Boxiang, Zhang Yu and Luo Nan. Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China. : Cancer management and research. 2019.